Mitsubishi Tanabe Pharma America

We wish everyone a happy and healthy holiday season. We look forward to using this time to rest and recharge, so that we can come back in the New Year to continue advancing scientific research for debilitating diseases like #ALS.  

Explore our recent announcement. Learn more here: https://bit.ly/4ixOgkK

As we reflect on this past year, we want to thank our team and entire network of partners for their continuous drive to solve complex problems in science and medicine. Together, we will continue to apply our KAITEKI model and strive to make a real difference in the lives of people living with serious and debilitating diseases.     Watch our end of year recap video below that highlights some of our work. #TeamMTPA 

Our team was thrilled to attend The International Alliance of ALS/MND Associations’ 2024 Alliance Meeting & Allied Professionals Forum in Montreal, Canada. Over the course of two days, members of the team met with ALS representatives from all around the world to discuss advancements that help support people living with ALS.     Thank you to everyone who contributed! 

Our team is looking forward to discussing the latest research from our Phase 2 and Phase 3 studies in Parkinson’s Disease at the 2024 Parkinson Study Group Annual Meeting in Nashville.     Learn more here: https://bit.ly/4fXkDYu 

We are honored to attend the Motor Neurone Disease (MND) Association's 35th International Symposium on ALS/MND, where we will share 10 presentations highlighting our latest research in ALS including safety profiles and real-world studies. Our team is excited to connect with Alliance members, researchers and other attendees from around the world to discuss research in #ALS. Learn more about our presentations: bit.ly/3ZiVPTN

Congratulations to the Davis Phinney Foundation on their 20th anniversary. This important organization has spent the last 20 years providing unwavering support to the Parkinson’s disease (PD) community. We’re proud to work together, with a shared goal of understanding and raising awareness of the unmet needs of people living with PD and their families. 

How has Parkinson’s disease (PD) evolved over the years? Ryan Case, PhD, Senior Medical Director, recently shared his insights on the shifting landscape with pharmaphorum. The discussion explored his perspective on the latest advancements and exciting areas of innovation that are driving progress, as well as how MTPA’s guiding philosophy – the KAITEKI principle – shapes our work and commitment to people living with Parkinson’s disease. We applaud Ryan’s dedication to the PD community and are proud to have him on our team. Read the full article here: https://bit.ly/4fA9hZU

This #NationalFamilyCaregiversMonth, we recognize the dedication and compassion of caregivers, including those within our team like Greg Mitchell, Regional Business Director at MTPA.     Over the span of four years, Greg's family of five quickly became 9, as he and his wife moved both of their parents from Texas to Pennsylvania to help care for them.     As Greg puts it, “While there were many family dynamic changes with the blending of two families, now in caregiver-mode – this was the best decision we could have made.”    Read more about his story below as he sheds light on the challenges and rewards of caregiving.     #TeamMTPA #NFCMonth  

Hear from Nancy Bayerlein, Senior Director, Patient Engagement & Support, on the importance of reducing the burden placed on millions of family caregivers across the nation. #NationalFamilyCaregiversMonth